137 related articles for article (PubMed ID: 21905596)
1. [Treatment effects of co-amoxiclav (Amoxiclav 2x) in acute exacerbation of severe chronic obstructive pulmonary disease: clinical evaluation].
Andrijević I; Povazan D; Andrijević L; Povazan A; Milutinov S
Med Pregl; 2011; 64(3-4):178-82. PubMed ID: 21905596
[TBL] [Abstract][Full Text] [Related]
2. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome.
Hoepelman IM; Möllers MJ; van Schie MH; Greefhorst AP; Schlösser NJ; Sinninghe Damsté EJ; van de Moosdijk CN; Dalinghaus WH; Eland ME; Mol SJ; Rozenberg-Arska M
Int J Antimicrob Agents; 1997 Jan; 9(3):141-6. PubMed ID: 9552709
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.
Cazzola M; Vinciguerra A; Beghi GF; Paizis G; Giura R; Madonini V; Fiorentini F; Consigli GF; Tonna M; Casalini A
J Chemother; 1995 Oct; 7(5):432-41. PubMed ID: 8596127
[TBL] [Abstract][Full Text] [Related]
4. Amoxicillin concentrations in relation to beta-lactamase activity in sputum during exacerbations of chronic obstructive pulmonary disease.
Brusse-Keizer M; VanderValk P; van der Zanden RW; Nijdam L; van der Palen J; Hendrix R; Movig K
Int J Chron Obstruct Pulmon Dis; 2015; 10():455-61. PubMed ID: 25767383
[TBL] [Abstract][Full Text] [Related]
5. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.
Miravitlles M; Llor C; Naberan K; Cots JM; Molina J;
Respir Med; 2005 Aug; 99(8):955-65. PubMed ID: 15950136
[TBL] [Abstract][Full Text] [Related]
6. Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease.
Sethi S; Anzueto A; Miravitlles M; Arvis P; Alder J; Haverstock D; Trajanovic M; Wilson R
Infection; 2016 Feb; 44(1):65-76. PubMed ID: 26370552
[TBL] [Abstract][Full Text] [Related]
7. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
Starakis I; Gogos CA; Bassaris H
Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD.
Wilson R; Anzueto A; Miravitlles M; Arvis P; Haverstock D; Trajanovic M; Sethi S
Int J Chron Obstruct Pulmon Dis; 2015; 10():985-93. PubMed ID: 26082623
[TBL] [Abstract][Full Text] [Related]
9. [Infectious exacerbation of chronic obstructive pulmonary disease: prospects for high-dose levofloxacin therapy].
Astaf'ev AV; Styrt EA; Sinopal'nikov AI
Klin Med (Mosk); 2013; 91(3):44-50. PubMed ID: 23789452
[TBL] [Abstract][Full Text] [Related]
10. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections.
Hoepelman AI; Sips AP; van Helmond JL; van Barneveld PW; Neve AJ; Zwinkels M; Rozenberg-Arska M; Verhoef J
J Antimicrob Chemother; 1993 Jun; 31 Suppl E():147-52. PubMed ID: 8396086
[TBL] [Abstract][Full Text] [Related]
11. [ANTEAB: a study of early antibiotic therapy in intensive care management of acute exacerbations of chronic obstructive lung disease].
Fartoukh M; Similowski T; Brun-Buisson C;
Rev Mal Respir; 2004 Apr; 21(2 Pt 1):381-9. PubMed ID: 15211249
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis.
Read RC; Kuss A; Berrisoul F; Kearsley N; Torres A; Kubin R
Respir Med; 1999 Apr; 93(4):252-61. PubMed ID: 10464889
[TBL] [Abstract][Full Text] [Related]
13. Frequency of Streptococcus pneumonia and Haemophilus influenza in acute exacerbation of chronic obstructive airway disease and their sensitivity to levofloxacin.
Furqan S; Paracha SA
J Pak Med Assoc; 2014 Apr; 64(4):399-402. PubMed ID: 24864632
[TBL] [Abstract][Full Text] [Related]
14. Three vs. 10 days of amoxycillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study.
Roede BM; Bresser P; El Moussaoui R; Krouwels FH; van den Berg BT; Hooghiemstra PM; de Borgie CA; Speelman P; Bossuyt PM; Prins JM
Clin Microbiol Infect; 2007 Mar; 13(3):284-90. PubMed ID: 17391383
[TBL] [Abstract][Full Text] [Related]
15. Relation between amoxicillin concentration in sputum of COPD patients and length of hospitalization.
Brusse-Keizer M; ten Bokum L; Movig K; van der Valk P; Kerstjens H; van der Palen J; Hendrix R
COPD; 2011 Apr; 8(2):66-70. PubMed ID: 21495834
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial therapy of acute infectious exacerbation of chronic obstructive pulmonary disease.
Chelidze K; Jgarkava M
Georgian Med News; 2008 Jun; (159):27-30. PubMed ID: 18633147
[TBL] [Abstract][Full Text] [Related]
17. A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections.
Zachariah J
J Antimicrob Chemother; 1996 Jun; 37 Suppl C():103-13. PubMed ID: 8818851
[TBL] [Abstract][Full Text] [Related]
18. [Clinicomicrobiological monitoring of patients with exacerbation of chronic bronchitis treated with antibacterial drugs].
Dvoretskiĭ LI; Dubrovskaia NV; Grudinina SA; Filimonova OIu; Iakovlev SV; Sergeeva EV; Sidorenko SV
Ter Arkh; 2006; 78(3):25-35. PubMed ID: 17019954
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease.
Llor C; Moragas A; Hernández S; Bayona C; Miravitlles M
Am J Respir Crit Care Med; 2012 Oct; 186(8):716-23. PubMed ID: 22923662
[TBL] [Abstract][Full Text] [Related]
20. [Not all exacerbations of chronic obstructive pulmonary disease should be treated with antibiotics].
Nielsen SK; Lange P
Ugeskr Laeger; 2017 Apr; 179(15):. PubMed ID: 29332624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
